Celsion Corporation - נכסים נקיים למניה בודדת IMNN

The foundation of Imunon, Inc. (IMNN) growth is the recruitment of leading biologists to develop DNA vaccines within a scientific environment. This book value per share chart confirms this trajectory, where the current parameter equals 0.90. Development relies on a technological base of cancer immunotherapy, although scaling is constrained by high R&D costs and the production of gene vectors.

Ensuring the uninterrupted supply of nucleotides for cancer therapy requires significant capital expenditures, which is reflected in the book value per share of Imunon, Inc. (IMNN). This indicator is calculated as the difference between total assets and liabilities divided by the number of shares, allowing an investor to assess the intrinsic value of the business and the risks of asset undervaluation relative to its actual net resources.